ScienceLife Sciences

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Play

Open in

68 episodes
daily
Avg 5 min
English

Episodes 68

Newest Oldest Longest

All8 Unplayed8 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

July 20 · 3 min
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
In today's Pharmaceutical Executive Daily, Invivyd's chief scientific officer discusses a platform designed to predict future viral variants ahead of time, Bristol Myers Squibb expands its AI compute infrastructure with Nvidia to build what it calls the most powerful AI factory in life sciences, and FDA clears Consano Bio's IND for a non-opioid biologic targeting chronic sciatica.
July 17 · 2 min
Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta
In today's Pharmaceutical Executive Daily, FDA converts Fabhalta's accelerated approval to full approval for IgA nephropathy, a Pharmaceutical Executive commentary argues AI-driven patient support still can't replace human connection, and Jasper Therapeutics closes its acquisition of Kira Pharmaceuticals in a deal combining a three-asset immunology pipeline.
July 16 · 3 min
Pharmaceutical Executive Daily: FDA Approves Lipfendra
In today's Pharmaceutical Executive Daily, FDA approves Merck's Lipfendra as the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly agrees to acquire AtaiBeckley for up to $3.8 billion, and a Pharmaceutical Executive podcast explores how better questions, not just more data, define strong biopharma leadership.
July 16 · 7 min
Hiring and Fostering Top Talent
Nuvation CEO David Hung discusses his leadership style, success stories for building camaraderie, and his inspiration for joining the pharma and biotech industry.
July 16 · 27 min
The Power of Better Questions: How Great Leaders Balance Risk, Growth and Curiosity
What separates exceptional life sciences leaders from merely capable ones? According to veteran biopharma executive Craig Tooman, it often comes down to one deceptively simple skill: asking the right questions. In this episode of Leading Edge with Ken Banta, Tooman reflects on the lessons from a career journey spanning clinical, operational, financial and capital market roles, including as the CEO of Silence Therapeutics, and shares how curiosity, disciplined thinking and openness to unexpected opportunities have shaped his leadership philosophy. Joined by Ken Banta, The Vanguard Network founder and CEO, and Pharmaceutical Executive's Mike Christel, the discussion examines how leaders can balance prudent risk management with long-term growth, cultivate cultures where cross-functional teams challenge assumptions and avoid the groupthink that often stifles innovation. The conversation also explores the changing role of AI in decision-making, why human judgment remains indispensable and how today's CEOs must think differently about funding, scientific strategy and organizational adaptability in an increasingly complex industry.
July 15 · 3 min
Pharmaceutical Executive Daily: FDA Approves Reytorpyk for Advanced Breast Cancer
In today's Pharmaceutical Executive Daily, Steer Bio discusses its regenerative cell therapy platform for cancer-related lymphedema, FDA approves Celcuity's Revtorpyk as the first pan-PI3K and mTORC1/2 inhibitor for advanced breast cancer, and Insilico Medicine enters a strategic alliance with Bora Pharmaceuticals worth up to $2.5 billion.
July 14 · 2 min
Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik
In today's Pharmaceutical Executive Daily, AstraZeneca acquires global rights to Dizal Pharmaceutical's lung cancer drug Zegfrovy in a deal worth up to $1.5 billion, FDA approves a subcutaneous formulation of Leqembi for early Alzheimer's disease, and a pharmacy executive weighs in on the education gap facing patients starting GLP-1 therapies.
July 13 · 2 min
Pharmaceutical Executive Daily: FDA Issues CRL to Elevar Therapeutics
In today's Pharmaceutical Executive Daily, a new industry analysis warns that direct-to-patient pharma platforms are scaling faster than the safety infrastructure needed to support them, FDA issues a complete response letter to Elevar Therapeutics over manufacturing deficiencies in its liver cancer combination therapy, and Insilico Medicine deepens its partnership with China Medical System Holdings in a new AI-powered drug discovery collaboration worth up to $177 million.

Showing 61–68 of 68 episodes